ESMO Open

Papers
(The H4-Index of ESMO Open is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Editorial Board301
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)212
Editorial Board183
87P Characteristics and outcomes of 11 patients with myoepithelial tumors: The Gustave Roussy experience131
94P Efficacy of first-line pembrolizumab in elderly patients with advanced non-small cell lung cancer with high PD-L1 expression124
PP289 Potential anti-tumour therapy in nasopharyngeal carcinoma: MDM2 siRNA-based approaches118
Letter comments on: Drug–drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of patients with metastatic breast cancer118
OP01-2 Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors115
107P Clinicopathologic features of breast cancer patients in a single tertiary hospital in the Philippines109
258P Real-world (rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherap106
284P Risk assessment for systemic recurrence in HER2-low breast cancer: Evaluating hormone receptors and immunohistochemical profiles103
225P Impact of cyclin inhibitors (CDK4/6i) on immune cell populations in first-line treated metastatic breast cancer (mBC) patients94
266O Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: Results from an international cohort study93
ESMO88
70P Development and validation of a machine learning (ML) nomogram to predict RSClin results and guide adjuvant treatment of node-negative (N0) hormone receptor-positive (HR+)/human epidermal growth f87
70P Invasive lobular breast cancer (ILC), an overlooked subtype in clinical trials86
PP018 PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling85
103P Impact of Prosigna test on treatment decision in lymph node-negative early breast cancer: A prospective multicenter study (EMIT1)85
118P Real-world treatment patterns and clinical outcomes among high risk, early stage HER2-negative breast cancer (BC) patients in Alberta, Canada84
200P OlympiAD: Exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC)84
267P Ultrasound-guided injection with or without rehabilitation exercise in breast cancer survivors with subacromial-deltoid bursitis: Long-term results of a pilot randomized clinical study80
Editorial Board77
OP27 A phase II study of neoadjuvant erlotinib for operable stage II or IIIA non-small cell lung cancer with epidermal growth factor receptor activating mutations77
47P Sarcoma in the Czech Republic: Update data through 2021 including epidemiology, patients flow and treatment outcomes75
51O The European Prospective Investigation into Cancer and nutrition cohort (EPIC): A gateway to rare cancer epidemiological research – Insights from the EPIC Rare Cancers Working Group75
100P Combinatorial treatment strategies for overcoming the immunotherapy resistance in soft tissue sarcomas74
62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutatio74
107P The actin cytoskeleton as a new target structure for metastasizing osteosarcoma72
PP049 Redistribution of 8-oxo-G/AP sites hot spots mediated transcription alteration is a novel and ubiquitous mechanism in EGFR-TKI resistance of NSCLC71
Editorial Board69
8P Clinicopathological features and the role of adjuvant therapy in the management of gastrointestinal verrucous carcinoma68
10P The risk of second primary lymphoma in colorectal cancer: An updated SEER analysis 2000–202062
97P Cost-effectiveness of TTFields in addition to standard systemic therapy for stage IV non-small cell lung cancer patients following progression on or after platinum-based chemotherapy61
129P FDG PET imaging of symptomatic chest wall myositis following stereotactic body radiation therapy (SBRT) for patients with early stage cell lung cancer60
38P Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cance59
128P Innovative limb salvage: Liquid nitrogen approach in reconstruction after bone tumor resection57
199P Radiomics analysis predicts chemoimmunotherapy advantage over chemotherapy alone in extensive-stage small cell lung cancer (ES SCLC)56
55P The SOS inhibitor BAY293 contributes to amplified vertical inhibition of the MAP kinase pathway in human melanoma cells56
146P The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis55
148P Identification of potential predictive biomarkers for ovarian cancer chemotherapy response55
57P Two cases of adult rhabdomyosarcoma of the head and neck successfully treated with pazopanib54
83P Cost-effectiveness analysis of talazoparib maintenance treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US53
174P Endocrine disruptors and life STILe in patients carrying BRCA pathogenic VAriants with breast and/or ovarian CAncer and women without neoplasm: The STILVARCA study52
63P Redefining the role of CA 19-9 as a prognostic marker in epithelial ovarian cancer50
180P Improving the referral pathway for breast cancer patients: Lessons learnt from 1-year pilot50
232P Real-world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom49
68P Prognosis of ovarian cancer patients with the Mexican founder mutation (a BRCA1 long genomic rearrangement) compared with other BRCA1/2 mutations49
63P Activity and safety of FGFR inhibitors in pan-cancer patients with FGF/FGFR alterations and advanced malignancies: A pooled analysis of 7 phase I/II trials48
39P A validation study of a self-testing capillary kit, the rhelise kit for therapeutic dose monitoring (TDM) of tamoxifen, Z-endoxifen, and 4-hydroxytamoxifen in breast cancer patients48
0.10035991668701